A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability
More about Open Access at the CrickAuthors list
Elizabeth A Kuczynski Giulia Morlino Alison Peter Anna ML Coenen-Stass Jennifer I Moss Neha Wali Oona Delpuech Avinash Reddy Anisha Solanki Charles Sinclair Dinis Calado Larissa S CarnevalliAbstract
Peripheral T-cell lymphoma (PTCL) represents a rare group of heterogeneous diseases in urgent need of effective treatments. A scarcity of disease-relevant preclinical models hinders research advances. Here, we isolated a novel mouse (m)PTCL by serially transplanting a lymphoma from a germinal center B-cell hyperplasia model (Cγ1-Cre Blimp1fl/fl ) through immune-competent mice. Lymphoma cells were identified as clonal TCRβ+ T-helper cells expressing T-follicular helper markers. We also observed coincident B-cell activation and development of a de novo B-cell lymphoma in the model, reminiscent of B-cell activation/lymphomagenesis found in human PTCL. Molecular profiling linked the mPTCL to the high-risk "GATA3" subtype of PTCL, showing GATA3 and Th2 gene expression, PI3K/mTOR pathway enrichment, hyperactivated MYC, and genome instability. Exome sequencing identified a human-relevant oncogenic β-catenin mutation possibly involved in T-cell lymphomagenesis. Prolonged treatment responses were achieved in vivo by targeting ATR in the DNA damage response (DDR), a result corroborated in PTCL cell lines. This work provides mechanistic insight into the molecular and immunological drivers of T-cell lymphomagenesis and proposes DDR inhibition as an effective and readily translatable therapy in PTCL.
Journal details
Journal EMBO Molecular Medicine
Volume 14
Issue number 6
Pages e15816
Available online
Publication date
Full text links
Publisher website (DOI) 10.15252/emmm.202215816
Europe PubMed Central 35510955
Pubmed 35510955
Keywords
Related topics
Type of publication